BEAM Q3 2023 Earnings — Beam Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

BEAMBeam Therapeutics Inc.

$3B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$17M+8.8% YoY

Gross Profit

-$83M-481.9% margin

Operating Income

-$108M-629.7% margin

Net Income

-$96M-558.9% margin

EPS (Diluted)

$-1.22

QoQ Revenue Growth

-14.5%

Cash Flow

Operating Cash Flow

-$90M

Free Cash Flow

-$98M

Stock-Based Comp.

$26M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$512M

Stockholders' Equity

$779M

Cash & Equivalents

$169M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$17M	$16M	+8.8%
Gross Profit	-$83M	-$69M	-19.2%
Operating Income	-$108M	-$91M	-18.6%
Net Income	-$96M	-$110M	+12.3%